®”¯•°”›±—±ÿ²™”­ÿ
`
`¥¤¤¦§¨¨©ª«¬›£­¬”™¢¨
`
`ÿ”
`
`•ÿ–—˜™š›™œÿžÿŸ ¡ÿ˜œÿ¢š—£¤
`
`    
`




` ! "#$ 
`%&#'()* 

+,#-./-#,)&0 #-1#'& #'()2 ,2,3,"
`
`


`
`/&.,'&0/+ ,-4 .(#1#)205,)#)#2%#42 ,#-)#.
`6#,-),") 4)#,#7',)28
`63#"9&,2

:;,&;#(

#.#"

." 1,)7/-(,&
`<=>?@AB=CADEF=GHIHC=J<HKHLHDCDEMCE=IAHDNL<HL=?L=LJ?CG<=>?@AB=CADEO?BHPQ?CGR@=K=CAHK=F=GHIHC=J
`SCHK=@LHAQDET?PHED@CH?JU?C<H=VDJW?XDPP?JT?PHED@CH?
`
` ,-,#3,"/,),+1,--,),"6,-,+1,
`
`YZ[\]^_Z`abc^c^dYe^[fdghYij^]k`_c^\]^dbd^l]^m_b]cn\[opn^p`Z`bocZa[\qo`rn^cZo^r^c`pcZ`[ba`fc^_
`\ac^\]dst]frq`[\k]\e`oudrboor\o`_fob[^]Z^q^c\[d\khYi[`ao^_bc^\]b[`]\n`]c`[^]l`b[ov_o^]^_boc[^bod
`^]Zfrb]dsw`d^dcb]_`c\drboor\o`_fob[^]Z^q^c\[d^do^x`ovc\q`bd^l]^m_b]cZf[po`c\cZ`^[fd`^]abc^`]cds
`tdvdc`rbc^_bdd`ddr`]c\k_\rq^]bc^\]d\k^]c`[k`[\]b]py\[]\e`ob]c^zZ`abc^c^dYe^[fdbl`]cdk[\r d`e`[bo
`p^kk`[`]cr`_Zb]^dc^__obdd`dnbda`[k\[r`p^]e^c[\sY\rq^]bc^\]d\k^]Z^q^c\[dn^cZp^kk`[`]cr`_Zb]^drd\k
`b_c^\]_\]d^dc`]covp`r\]dc[bc`pr\[`dv]`[lvcZb]p^p_\ra\f]pdn^cZd^r^ob[r`_Zb]^drd\kb_c^\]s{Z`d`
`[`dfocddfll`dccZbc_\rq^]bc^\]d\k^]Z^q^c\[dn^cZp^kk`[`]cr`_Zb]^drd\kb_c^\]dZ\fopq`a[^\[^c^|`pk\[
`bdd`ddr`]c^]_o^]^_boc[^bodk\[_Z[\]^_Z`abc^c^dYe^[fd^]k`_c^\]s
`
`%(.#-(,)#)#2%3#42}5%~#.0,-)#.#2+€"
`€#",(,)(1,+#.)(,.#),"/)),2

.,2)#+),"
`+##.,2.2,-(.#-&#.0,-),"}‚~ƒ2)#+),20)(,
`(,)(-,14",.0-(.#-5%#.0,-)#.,"#-)"2)#-
`#.-,2,#.(2#)#„)#.2."+,"#--2)2,),")-+
`#-)#.224-(2-#(2#2."(,)-,4--#.+3,
`)(,.,…))",-",2}~ƒ00,-)#3,."1,)),),),"
`)(,&05%-4",00,-)#3,&2),+ )(#2)#",}~
`%4,.)#.),0,.12,")(,&0-(.#-5%#.0,-)#.
`,24)2#.242)#.,",2.2,2#.4'(&† 0)#,.)2."#2
`--+.#,"1&2#'.#‡-.))…#-#)&
`,.)&,5%

)(,
`+2),3,.)',.)&,#.)(,.#),"/)),2

,2."2,22
`€,))(,&€#)(,'&),"#.),0,.42#13##.

€#)(
`,2.2,),20‚)‚† }

~7(,2,#+#))#.2(3,
`24,".#.),.2,"4'"#2-3,&,00)

,24)#.'#..4+1,
`0+#2#.'-+4."2}~
`5,)#)#2% 3#42,#-)#.)ˆ,2-,#.)(,-&)2+

`€#)()(,,#-)#.-+,…1,#.')#'()&22-#),"€#)(##"
`+,+1.,2}~;,&-+.,.)20)(,,#-)#.-+,…
`#.-4", 2,3,+#2#.' .)#3#)',)2

#.-4"#.' )(,
`/‚ ),2,.")(,/‰ ",,.",.)  &
`+,2,.4+1,0-."#"),),2,#.(#1#)2}Š 2~€(#-(
`(3,,…-,,.)),.-&#.3#)(3,1,,.",3,,"}



~
`2,3,0)(,2,-+4."2(3,21,,.,34),"#.(2,
`
`  )#2

€#)(,.-4'#.',24)2}



‹

~ ,2#2).-,
`))(#2-220#.(#1#)2(21,,.",2-#1,"

€#)(2+,+4)
`)#.2-.0,#.'-22,2#2).-,)2,3,-+4."2}



`

‚

~
`7(,/‰ &+,2,#22,22,.)#03#,#
`-)#.

.".4+1,0.4-,2#",#.(#1#)2."...4-,
`2#",#.(#1#)2} 2~0)(,5% &+,2,€#)(),.)
`-)#3#)&#.3#)."#.,&-#.#-)#2(3,1,,.",2-#1,"
`}







~ ,2#2).-,)1)(.4-,2#",."..
`.4-,2#",#.(#1#)2#.3#)(21,,.",2-#1,"}

‚

~
`
`:%,2."#.'4)( ##.'"",22$‹
`#+.6#3,

%
`



%‹‹Š(.,$}~‹…$}~
`ƒ+#$"€&,2’4-2","4
`8Š41#2(,"(,"0#.).6,-,+1,
`
`9,(3,22,22,".4+1,0-+1#.)#.205%#.(#1#)2
`€#)(2,3,+,-4)',)2-4,.)&#.",3,+,.)

42#.'
`.5%',.)&,,#-.12,"4-#0,2,,),2&2),+
`w`ao^_\]_\]dc[f_cds7(,‰ ‚,#-.#2241',.+#-
`5% ',.)&,1,#-.€(#-(-.)#.2",,)#.0
`2,#.,#./ ."(21,,.,3#42&",2-#1,"}‚~7(,
`‡,Œ&4-#0,2,',.,€2#.2,),"#.)(,‰ ‚,#-.

#.
`+..,,3#42&",2-#1,"}~

)-,),4-#0,2,.,
`+&-#.(2().20,2,042#.),#.}ƒ ~.")(,,
`#-.}‰ ‚ƒ ~‰#,Œ&

)(,RDAHCNL>Q@?PHL4-#0,2,
`',.,€2+#‡,"42#.'#+,2-"#.'0)(,2- ,2)#-
`)#.2#),€#.'+#‡-)#.

1)()(,‰ ‚2+#"."
`4-#0,2,Š% "4-)€,,,2)#-)#."#',2),"€#)(2- 
`#')#.€2)(,.-#,"4))#.2,))(,4-#0,2,',.,#.
`(2,€#)()(,.,+&-#.(2().20,2,',.,

-,)#.'
`)(,",2#,"‰ ‚ƒ ,#-.7(,2,Ž4,.-,0)(,,#
`-.€23,#‡,"1&62,Ž4,.-#.'
`Y`oo_focf[`s54+.(,)+54(-,2}ˆ#."'#0)
`0+.-#2%(#2#

/-#2 ,2,-( .2)#)4),



%~
`."‰ ‚ƒ -,22)1&,…,22#.')(,‰ ‚ƒ ,
`#-.€,,'€.)%."† % #.641,--2+"#‡
`-)#.0ƒ',2+,"#4+ 24,+,.),"€#)(+ '4
`)+#.,

4.#)2+,.#-##.

‘'+2),)+&-#.

."
`† 0,)13#.,2,4+‰ ‚ƒ -,2€,,""#)#.&
`'€.#.)(,,2,.-,0‘'+0
`‚
`{[b]dk`_c^\]b]p_o\]`d`o`_c^\]s7(,‰ ‚ƒ 2+#"
`€2#.,#„,"€#)(/-  .3#)).2-#)#.} ,'2-#)
`+1#.~€2-#,"4)--"#.'))(,+.40-)4,2#.
`2)4-)#.)&#,"‰ ‚ƒ 7.20,-)#.€2,
`0+,"2,3#42&",2-#1,"}~4(4.","+#-#),2
`054(-,242,.2#.}-,2+~€2-,"#.
`‚-+ -43,)),€#)(‘'0‰ ‚ƒ 7(,+#…)4,
`€2,,-)),"}‰# "
`,.,Š42,~) ."‹
`‘.").20,,")-+)#224,-4)4,"#2(
`‚)
`‘'+€2"",")‚(

.")(,+,"#4+ €2-(.',",3,&
`)‚"&2 ."#3#"4
`‚,2#2).)-.#,2€,,3#2#1,
`€#)(#.)€,,ˆ2 ."#3#"4-.#,2€,,(3,2),"."
`,….","0-(-),#„)#.04-#0,2,,…,22#.
`
`
`
`1
`
`GIL2021
`I-MAK, INC. V GILEAD PHARMASSET LLC
`IPR2018-00123
`
`

`

`3006
`
`NOTES
`
`J. VIROL.
`
`Luciferase compound assay. BM4-5 FEO cells were seeded
`into 96-well plates at a density of 10,000 cells per well in 100 p.l
`medium. After allowing 4 h for attachment, compounds were
`added to wells at the specified concentrations. All conditions
`were run in triplicate. Cells and compounds were incubated for
`48 h. The luciferase assay (Bright-G10; Promega) was carried
`out according to the manufacturer’s instructions. Luciferase
`activity was determined using a microplate luminometer (Ve-
`ritas microplate luminometer; Turner Biosystems). The rela-
`tive light units (RLU) for each condition were reported as the
`mean i the standard error of the mean for the three wells.
`
`Compounds tested. Compounds tested included two pep-
`tidomimetic HCV PIs, BILN 2061 (16) and a Vertex PI (19)
`(Vicki Sato, Vertex Pharmaceuticals, Cambridge, MA); a
`GlaxoSmithKline trans-lactam PI active-site mimic (2) (Karen
`Romines, GlaxoSmithKline, Research Triangle Park, NC); one
`nucleoside analog HCV RNA—dependent RNA polymerase
`inhibitor (RdRpI), 2’-C-methyladenosine (10) (William Lee,
`Gilead Sciences, Foster City, CA); one nonnucleoside GSK
`benzo-thiadiazine RNA polymerase inhibitor directed at
`the
`“thumb” region of the polymerase (Karen Romines, Glaxo-
`SmithKline) (9); and alpha interferon (Interferon-OLA; Sigma-
`Aldrich).
`The 50% inhibitory concentration (ICSO) of each compound
`was determined independently and used to set the range of
`concentrations used for the synergy experiments. Each com-
`pound was tested singly and in combination at two twofold
`serial dilutions above and below the ICSU. The ratio of the two
`compounds tested remained fixed across the dosing range.
`Potential cytotoxicity of individual compounds and all combi-
`nations was assessed using a luminescent ATP-based cell via-
`bility assay (Cell Titer-G10; Promega).
`Data analysis. Determinations of compound interactions
`were based on the median-effect principle and the multiple
`drug eifect equation as described by Chou and Talalay (6).
`Combination indices (CIs) were determined using Calcusyn
`(Biosoft) for each experiment at the ICSO, IC70, and IC90 levels.
`In total, 15 combinations were evaluated with from three to
`five replicates per condition; this yielded a total of 61 data
`points per CI level analyzed. A CI of <09 was considered
`synergistic, a CI of 20.9 or 51.1 was considered additive, and
`a CI of >1.1 was deemed antagonistic.
`Statistical analysis. At each of the three inhibitory concen-
`trations evaluated (ICSO, IC70, and IC90) the C15 in the three
`synergy groups were compared using a linear mixed-effects
`model allowing for different means in the three synergy groups
`and random effects for the individual drug combinations. The
`random effects were not significant (likelihood ratio test), in-
`dicating no statistical difference in CI values between the an-
`tiviral compound combinations in the same synergy group. The
`CI replicates were further compared between synergy groups
`by using the Wilcoxon rank test.
`Synergy of small molecular inhibitors. Transfection of Huh-
`7.5.1 cells with BM4-5 FEO RNA yielded numerous (>50)
`G—418-resistant clones. Individual clones were expanded and
`assessed using the luciferase assay to determine the individual
`clones with highest RLU per cell. Four clones yielded from
`30,000 to 50,000 RLU per 10,000 cells at 48 h (data not
`shown); these clones were expanded and used for all subse-
`quent studies.
`
`TABLE 1. Activities of different small molecular inhibitors in the
`BM4-5 replicon
`HCV BM4-5
`replicon
`1C5” (“My
`
`Compound
`
`Structure
`
`lFN—alpha
`
`Vertex [’1 (l9)
`
`T”
`will)?
`
`up
`
`3.59 ll 1 ‘ml : 0.41
`
`‘v
`
`293.10 : 5392
`
`BILN 206| (I6)
`
`9.44 10.88
`
`GSK Pl (3)
`
`2"-C-mcthyladcnosinc(10)
`
`fii'g
`
`GSK NM (9)
`
`““10
`
`308.6 : 28.9
`
`427.2;ill
`
`3826 1 460.2
`
`
`
`“ The ICSO is the average : standard error of mean of the results from at least
`three independent experiments.
`
`The IC50 for each of the individual compounds is listed in
`Table 1. C150, C170, and C190 refer to the combination index at
`the ICSO, IC70, and IC90, respectively, of each drug. All com-
`pounds tested were additive (C150 and C170) or mildly syner—
`gistic (C190) with alpha interferon. Antagonism was not dem-
`onstrated for any combination of small molecular inhibitors,
`including compounds targeting the same viral protein. Signif-
`icantly more synergy was demonstrated between compounds in
`the group combining two small molecular inhibitors targeting
`the same viral enzyme (in this case NS3 protease) than be-
`tween the group of compounds combined with alpha interferon
`at both the C170 (P = 0.043) and C190 (P = 0.017) levels. There
`was no significant dilference between the groups at the C150
`level (P = 0.108) (Fig. 1). Similarly, the group consisting of two
`inhibitors with different viral targets showed significantly lower
`combination indices than either of the other two groups, i.e.,
`compounds with interferon (P < 0.001 at all levels) or com—
`pounds with same mechanism of action (P = 0.038 and 0.037
`at the CI50 and C170 levels, respectively). The comparison of
`Clgos between small molecular inhibitors with the same and
`different viral targets showed a trend toward a lower combina-
`tion index in the group with two compounds with difierent viral
`targets (P = 0.056 at the C190 level) (Fig. 1). None of the
`compounds or combinations showed cytotoxicity at the con-
`centrations tested in the activity and synergy studies (data not
`shown).
`Small molecular inhibitors of the HCV protease and poly-
`
`
`
`1sen6Aq3mg‘33MemqejUO/5JO'UJSB'!A[//Zd11qwonpepeolumoa
`
`
`
`
`
`2
`
`

`

`›œ‚ˆž„žÿŸ†šÿ
`
`’‘‘“”••–—˜™ˆš™†•
`
`ÿ
`
`‚ÿƒ„…†‡ˆ†‰ÿŠŠ‹ÿŠŒŽÿ…‰ÿ‡„‘
`
`5h.,$$0
`
`!5/4 3$$0
`
`{|-$0$ %$   
`
` 

 7 

`  
`
`
` *

 $% 
`
` 
` 
`   
`
`
` 
`/ }

 
`

 ~"   

   0$




`
`    
`
`

`
` 
`    

` 
` 
` 

 
`
`






`
`
`
`  

`
`     
`
`
` 
`


`  
`     
` 
`
`
`

 
`
`
`
`
`  
`
`   
`

`
`  !!"
` 
`    
`
`
`
`
`
`   
`


`   !!"  
` 

 
`
`  
`
`# 



  
`
`
`
`
`        
`
` 
` 
` 
` 
` 
` 
`


` 

   
`   
`
`   
`

  
`
`# 


`

  
`
`
`
`        
` 
` 


`  
`
`   
`      #
`
`   

  $%
`
`  
`  
`
`
`

 
`"   
` 

 
`
`
` 
`     
` 
`
`& 
`
` ' 
`  ($%)
`
`


` 

`
` 
`    
` 
`
`    
`    
`    
`

      
` 
`    
`  
`
`
` *
`

`+  
` #
`  
`    
`   !)

    
`  

`  



$
` $$


`      
` #
`  
`
`  
` 
`


` 
`
`
`

,-,."/ 
`   
`
`    

`  
`  
`

` 
`  
`

 

    






`
`
`
`   
`      
`
` 
` 
`
` 

    
` 0,1,2331"
`4 
`
` 
`
`
`
`
`  
`
` 
`

    
`
`  

 
`




`     

`

 
`  
`/
`
`
`   

  
`
`  
` 
`
`

` 
`
`
` 
`
`
` 
`

 
` 

`
`

` 
`  
`
`     
`  5
` 

  


` 
`
`




`


`
`
` 
` 

`
`


`

     
` 
`
`
` 
`    
`
`   
`
` 



 
` 
`
`/
`+  
`   ,$$- 

 

  
`  64 7
`   )74    ! 
` -3$)32,1"
`
`89:989;<9=
`
`>?@AB?CDECFEGEHIICJEKE=LMNCDEOPQ?BRCAMSKEKEHA?E,$$1  
` 
`T
`   
`
`
` !) 

`
` 

* 
` 
` 
`

`
`  
`

UVWX1-$Y12
`,>MSZI[PC\EKECKE<E]AZMIPCKE\E\R[^IC=EHED?MSCKE8EGRQMPRMC_E=E
`GRMIPC`EK?^^PC>E_Aa?B?PCbEGE_AaIcAMCbEGE8ISdIZMCGE9E8Re?MPRMC
`KEGE=^AaIZCAMS;EbZ?fIS?E,$$3

`
` --  

-  
` +
`
` 
`
`T
`
`
`
`  
`
` 
`!43g1)   
`5h iX123Y1231
`3>ZcPaZRMNC`EHECKEGE>^aIZC`EKEKjkL?^^AMCAMSDE=EKAZNR^?PE,$$$
`/  
`
`   
`
`
`
`
`l
`

`
`   
`  
`

` 
` 
`  6
` 4   

UmX000Y0.,
`1>ZcPaZRMNC`EHEC>EnAP^IoC9E_E=?cAZSC`EKEKjkL?^^AMCnEHEFLQMIZaC
`AMSKEGE>^aIZE,$$2/  

  
`
`
`
`
`
` 
`6
` 4 %%% ,$$,)  mWWX0$-Y01
`-<QAMCHECbEGE8ISSoCKE_ZRL^pC=EFE\APCqE_IZI?ZACnEnAMNC>E
`=?SS?rL?C<E`EsAMMRtRL^RPC<E_R?PPRMC;EbLZjRaaIC>E\ZRL?MCKEDE
`ARL?uOPcA?^?C8E]IaQI^^CKEDAcI^CHEHvDILZILpC\E]?^?cRZ?ACAMS;E
`;NLoIMu]AE,$$3 
`#
`!!
`
`   


`  
`


`
`
`  
`
` !4-w 

   x  
`WyX,.3Y,.-
`2<QRLCbE<ECAMS_EbA^A^AoE%.1z 
`
` 


`   


`
`3
`
`

`

`¡‡¢ˆ£‡Ž¤Š¤ÿ¥Œ‡ ÿ
`
`˜——™š››œžŸŽ– Ÿ‡Œ•›
`
`ÿ‡
`
`ˆÿ‰Š‹ŒŽŒÿ‘ÿ’“”ÿ‹ÿ•Š–—
`
`<;;H O…EC
`
`cta…D
`
`    
` 

  
` 

 
`   


` 
`
` !"#$%&'&$(&)&*+,-"./0$1&2&3445$ 67&8&94#:6,:-.&;;<=>
`?   
` @    @ A B 

C@D 
`E@ F<<G<<H
`H:2- 6I:#I4&9&$'&J4K:"$1&*+0 KL- $M&1LKK $ 67%&8".+" II"4&
`;;<@  @ N@ @ A @    
`OC<>P  @@

OCQO>



 O 
`@
`  @RSGGT
`U/ 6 5$&$V&(&LWWX$M&V&(4/6#046$(&'"6Y%4:-5:$8& -IX$*&Z&
`1/ [$\&%L$3&1"+!:-K 6$*&J&% 0:#$8&9&Z466:K I/:-$&'&) -6#/ [$
`&(&3 #]:-$*&V L- $*&\ 5:-$3&%-::6[447$'&'&%L0#/ ++$&8 +:X$
`*&:+M:II/"4$9&8 I --46$%&*&^4WK 66$_&*+64 /$^&`&3/:6.$%&
`3/ 6$1&V/ 67:5 -$9&8&V::6 6$ 679&J&1 -"#5X&;;a

 b @ 
`@

  @ @@  @         @ A
` O>



 O
`@cQ A
`dd<H<<H<
`G;)+7-L]$*&\&$8&e-/ !I$(&\-445#$\&\/ 0$J&e&e- 5 #/$f&146.$1&\:- $
`Z&\/ 0$e& 67:$e&&3445$3&2&\:66:00$1&1&3 --4++$9&%&\ ++$8&
`\4##:-K 6$3&\L-+:"6$'&2&34+[:++$(&2&2 X$g&*&2+4-:#$V&%:00X$9&'&
`' W:K"6 $(&':46:$8&8 I34##$&9&8I8 #0:-#$(&)&J4K ##"6"$'&&
`M46$\&h4+ 6#5"$ 67&\&g+#:6&;;PC >@  @   
`@>
`

b

i>A>
`   

@    @ A
` O  @  cj

A
`kdHPU
`GG2-":7$8&h&$8&'&1/"WWK 6$V&9&9:77X$3&1K"0/$%&8 -"64#$2&'&
`%46I +:#$(-&$&^ L##"6.:-$8&" .4$%&3 -4#"$&/LK: Ll$*&3- l"$
`*&'"6$(&^4WWK 6$ 67(&`L&;;=   @ @>@ @  
`  @ A    O cj

mkdUUH
`G%4] +# KX$*&$*&*]+ #I $%&3"#n:[#5"$V&e -5$(&h&)++"6.,4:$8&
`g-+4[#5"$\&2:+7$ 67*&`&^4[:&;;To  @

   <pP>



>
`Gq>rGs>   rp<> s@ @

<pP>



>Gq>@ r<pP>s  @
`
`

 @ @  >  

    qAtOCQO



 O
`
`@Q j

A
`DuvPPT;
`G<%4] +# KX$*&$V&'"K$%&3"#n:[#5"$V&e -5$(&h&)++"6.,4:$(&\+44K$1&
`w6# W$(&x]:#+ I"#$J&1&8 6#4L-$%&V-"#/6 KL-0/X$8& K -+ $`&
`eX 0#5"$&^4$*&`&^4[:$8&g-+4[#5"$\&2:+7$ 67(&gy3466:++&;;P
`o   @ r<pP>s

@ @

 qAtOCQ>
`
`
`@   cj

A
`kdTT;<TT;H
`GP%L4$(&J&$M&M&\"I/54$ 673&1::.:-&;;G   @@   
`@ A   ct dRHGTH<
`G^"6-"I/#:6$^&$`&\:6/ K4L$^&h:7:K:X:-$8&9:"#:-$9&)&1:60z:6#$
`(&'&3 ++:z ${&24-6#$*&)-/ -70$(&3-46+:"6$9&'&3/ !:#$3&'&`46.$%&
`Z:/K"n$ 67%&%&10:"6K 66&;;PC>
` @  @ b @  QaDO
`;TGp@@ A  @   p @ A G
`@  |@ udG<PG<
`GT' K --:$&$e&3&*67:-#46$8&\ "+:X$e&\: L+":L$%&\4+.:-$e&\466: L$
`8&\4#$&9&3 K:-46$8&3 -0":-$8&%&34-7"6.+:X$*&8&2 LI/:-$Z&
`%4L7-: L$1&^&V [ "$%&VL54+z$'&' . I:$1&9&' e+ 60:$^&Z -z:#$
`8&*&e4L] -0$(&9 6I4L-0$9&)&1:60z:6#$%&9&10$\&1"K46: L$%&
`10:"6K 66$&J/",: L+0$`&1&J# 60-"n4#$1&8&h:+746$3&'&`46.$ 678&
`'+"6 #Y\-L6:0&;;< OC<@   N @  @  
`
`@   

N @ A O@kvGHTGHU
`G'"6$3&$3&*&% 0:#$\&%&9 4$&'&\-:66 6$(&9&2L+./LK$`&e&'L46.$
`(&&2- 60n$V&'"6$1&8 $`&`&h:"$9&\&e:-6"$ 67*&&V[46.&;;
`a  

 > @ 
`@  @@ N@ A 
` @   pt}>U;@

QaDO ;TGcQ A
`S~
`<THP<TUG
`GH'"6$3&$V&'"6$`&e&'L46.$\&%&9 4$`&`&h:"$&'&\-:66 6$(&9&
`2L+./LK$^&8&^#" 4$1&8 $(&e&8 l[:++$V&8&3400-:++$9&\&e:-6"$
`3&*&% 0:#$ 67*&&V[46.&;;Pa   @ 

 @ A
`  @   pt}>U;@

QaDO;TG @@ @ 
`

@

  @ 
` @ 
`cQ A
`dFG;HGGP
`GU'"6$V&$*&&V[46.$ 673&'"6&;;PA
` @   @@ A 
`OC<>OCP @   @

@@      @   
` @O  @  @

@  @ @O @@    
`
`  A
`kSPHPPU
`;'"6$V&$9&\&e:-6"$*&&V[46.$ 673&'"6&;;Tt}>U;p@ @ 
`A qAt€OC<>P@   p   @  @@  
` qA  
`  A
`R~GHG<GH
`G'L$'&$J&(&e"+40Y8 0" #$V&&10:[ -0$(&J&9 674+]/$9&e"0/ [ ++ $h&
`^:$e&e&^L 6.$'&'&V+:"6$^&84$ 67*&84++ &;;Pj@    >
`   @ @ @ A  @   
` 
`  A
`kST;TT
`'L7K:-:-$1&h&$&(&%- / K$)&\440#$)&8&8L-- X$*&1"KI4:$)&(&
`
`8 -5:+$(&*&%-4,+:-$g&*&2+4-:#$&\&g+#:6$&(&^ nL7 $ 679&'&
`' 2:K"6 &;; @  b @

OCQ

   


`@ A  @ @@  

 @@    @  @@
`
`  A
`kF;U;TU
`<8 66#$8&e&$(&%&8I^L0I/"#46$1&3&%4-746$M&V&9L#0."$8&1/"WWK 6$
`9&9:"674++ -$_&&%447K 6$V&V4L-X$8&'"6.$ 67(&V&*+,-:I/0&;;G
`=   @ @> @  
`@

N    @ @>
` @   @@
`   @ A@@


` 

 @
`D@ mRSUHUT
`P8".+" II"4$%&$(&)&J4K ##"6"$1&1&3 --4++$'&J4K:"$1&*+0 KL- $\&
`\/ 0$'&\ -0/4+4K:[$8&9&\4##:-K 6$*&3:II II"$'&2&34+[:++$9&
`34-0:#:$2&9&:$*&\&)+7-L]$V&'&%:00X${&1&^4L$9&'&' 2:K"6 $1&h&
`'L7K:-:-$8&8 I34##$&9&8I8 #0:-#$8&h&10 /+/L0$&\&g+#:6$
`&(&^ nL7 $ 67g&*&2+4-:#&;;<A@@  @    @ 
`  > @ @ >
` @    

@ @@   @ 
`A  @   cQ A
`dSPUGTPPUG;
`Z:LK 66$*&x&$Z&e&' K$^& / -"$&9&%-:0I/$J&)&h"+:X$J&(&
`' X7:6$ 67*&1&e:-:+#46&GUUHq@ A @

 @
`   @


`@  @ b @    >@@@C  SG;<G;
`TZ.LX:6$J&J&$*&J&% 0:#$'&'&%L0#/ ++$M&V&(4/6#046$\&%L$V&(&LWWX$
` 679&J&1 -"#5X&;;< @ b @@ A  O>
`
`



 O
`@  @

@    
`  
`A
`kd<<<;
`g+#:6$&\&$*&\&)+7-L]$'&\ -0/4+4K:[$\&\/ 0$8&9&\4##:-K 6$*&
`3:II II"$'&2&34+[:++$(&2&2 X$g&*&2+4-:#$V&'&%:00X$(&*&%-4,+:-$
`9&'&' 2:K"6 $)&(&8 -5:+$%&8".+" II"4$8&e-/ !I$8&h&10 /+/L0$
`(&)&J4K ##"6"$8&8 I34##$&(&^ nL7 $ 671&1&3 --4++&;;P
`>

@@>@

  @ @ @ @

     @ A
`  @  N    @
`@ ‚   
` 
` A
`kS<UPP<U<
`He:-:+#46$*&1&$*&x&Z:LK 66$8&8 -54["0n$(&8&':46 -7$ 67&&^4&
`GUUTqat>G

 @
`      @@ @p  

 >@ p
`@

 @ @ 
`C  duGHGHT
`U9::#"65$^&$1&_:Ln:K$3&h::."65$Z&24-:#0":-$*&! 6M"+:0$(&! 67:
`h:0:-"6.7:944"z$'&8IZ "-$1&eL-7X$(&3/L$ 67e&( 6#:6&;;ƒ @
` @@GQp
` >



 t}>U;p@@ A 
`@   q@k<P<
`<;94,:-0#$1&$%&3445#+:X$%&4-:$9&94,#46$&1/ [$^&\:-6#$8&\- 67+$
`1&2:006:-$%&^"++$)&w]:$V&V+LK]]$8&8 66"64$)&gy8 - $w&Z z:- $
``&JL$ 673&h #/"6.0"46&;;T @@GQp
` 




` GTTp@   

@ @@ qAt 
`@ 
`qAt G@  q@kkTU
`<G1 -- n"6$3&$J&V":WW:-$&\ -0:+#$\&^ 6n:+5 $x&8L/$8&h:+5:-$&
`h"6I/:-"6.:-$3&'"6$J&%-4##K 6$1&eL-7X$3&h::."65$^&9::#"65$1&
`_:Ln:K$ 67*&&V[46.&;;A@@  @    @@ @  
`qAtOC<@


`@   G@  @@ 

 
`GP

@

 N t}>U;q@kG
`<1/"K 5 K"$J&$8&^"z"5 0 $^&'L4$`&`&8 $1&V 6:54$V&1/"K404/64$
` 671&8L- 5 K"&;;P   @  N @ A  
`OC@

OCQ @ A O @  N @ A
`   ct dS<HPH
`<<J 6 ,:$`&$Z&1 5 K404$Z&)64K404$8&VL-4# 5"$)&x:7 $1&8 :5 [ $
`J&` K #/"-4$8&Z 5 . [ $3&^&3/:6$Z&V 6 n [ $1&V 5"6LK $ 67
`8&h 0 6 ,:&;;PC       @ @@ A 
` @   
` @    @  @

  >@@ca  o 
`uSFGGUGG<U
`<PJ-4nn"$3&$'&\ -0/4+4K:[$*&3:II II"$%&\" #"4+$'&e I"6"$1&*+0 KL- $
`2&Z -z:#$)&8L- .+" $%&e 46:## $x&V4I/$2&9&:$3&10:"65L/+:-$ 67
`%&8".+" II"4&;;<a    @

@@  @   @ A
`  @@ @  @ @ @ > 

   
`ct dd<TTU<TU
`<`"$8&${&J46.$*&15:+046$9&3/ #:$J&3/:6$*&e-46. X$1&'&\4.:6$*&V&
`1 5#:6 $2&%&Zz4-4.:$9&'&M:#:+:6 5$9&\&eX+:#$Z&\4L-6:$\&*&
`8 +I4+K$ 671&8&':K46&;;Tj@      @ CAqTp
`@ @ A OC<„P@   

 

O @>
`  b @

@ @  

> 
`@  cQ A
`
`SuH;HG
`<T_:Ln:K$1&$3&1 -- n"6$9&94Ln":-$*&J -- +$Z&\-"46$Z&24-:#0":-$1&
`%L]0 $&:I5K 6$V&2:++4[#$8&^L## "6$&3L0+:-$ 67(&_/ 6.&;;
` > @@   CAq;<;<Pp@qAt@   p@

` 

@
`
` @ @ A >G@   @ @

>
`  q@k<<<P
`
`4
`
`